| human | Q5 |
| P496 | ORCID iD | 0000-0001-7828-3854 |
| P1153 | Scopus author ID | 55970689200 |
| P734 | family name | Sforza | Q26726303 |
| Sforza | Q26726303 | ||
| Sforza | Q26726303 | ||
| P735 | given name | Vincenzo | Q16741113 |
| Vincenzo | Q16741113 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q55385744 | Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. |
| Q38263841 | Clinical management of advanced gastric cancer: the role of new molecular drugs. |
| Q55080669 | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. |
| Q55294897 | Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. |
| Q92060763 | EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer |
| Q90291956 | Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer |
| Q90643895 | First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age |
| Q39079626 | Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells |
| Q99349386 | Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q92741833 | Pembrolizumab in lung cancer: current evidence and future perspectives |
| Q38648300 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets |
| Q38996793 | Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. |
| Q42366615 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. |
| Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
| Q94647954 | The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer |
| Q24602875 | Treatment of gastric cancer |
| Q88608605 | Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program |
Search more.